AptD showed linear binding to daratumumab from 5 to 15 min after addition of TMB substrate and no significant binding to therapeutic mAb rituximab, polyclonal IgG, or three different IgG Kappa M-Igs purified from MM patient sera (Fig. 1b, right). Here, CUBN is linked to Miyoshi myopathy.